Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 10/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601332 | 0.93 | DHODH (0.57) | DHODHLMNAPDE10ATSHRPOLB | |
| Hydrochloric Acid SCHEMBL4602422 | 0.92 | DHODH (0.56) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL4601692 | 0.84 | LMNA (0.41) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL4601922 | 0.82 | DHODH (0.56) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL4602735 | 0.80 | PDE10A (0.56) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL4602935 | 0.80 | DHODH (0.53) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL5005010 | 0.75 | TACR3 (0.55) | CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL14610182 | 0.75 | TACR3 (0.58) | CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL4601100 | 0.74 | DHODH (0.56) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL14009520 | 0.73 | TACR3 (0.77) | TSHRCYP2D6CYP2C19CYP2C9TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287492-A1 | Alkylpyridyl Quinolines as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1915361-A1 | ALKYLPYRIDYL QUINOLINES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018466-A1 | ALKYLPYRIDYL QUINOLINES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287492-A1 | Alkylpyridyl Quinolines as Nk3 Receptor Modulators | ADORA3, KCNA3, TACR1 | DHODH 3718/4885LMNA 3173/4885PDE10A 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.